• AIM: To investigate whether DNA vaccine encoding herpes simplex virus 1 (HSV-1) glycoprotein C (gC) and glycoprotein D (gD) will achieve better protective effect against herpes simplex keratitis (HSK) than DNA vaccine encoding gD alone.
INTRODUCTION
H erpes simplex keratitis (HSK) is a chief worldwide blind-causing corneal disease that mainly caused by herpes simplex virus type 1 (HSV-1) infection [1] . After infection, HSV-1 virus will exist in host for a lifelong time [2] . Generally, in human there are 3 ongoing phases that finally contribute to the development of HSK, namely primary infection, latent phase and recurrent phase [2] . The antiviral medications, which is the main strategy for HSK management at present, just temporarily control symptoms of HSK, not eradicate the disease or virus [3] . As yet, no methods that can effectively control the spread of virus are available. Due to the ability of causing specific immune response against HSV-1, HSK vaccines are thought to be the most effective approach to deal with HSK [4] [5] . Among them, DNA vaccine is getting particular attention. After being inoculated, the target genes of DNA vaccine are expressed and presented in host cells and could produce strong and sustained cellular and humoral immune responses [6] [7] . In some fields such as Venezuelan equine encephalitis, cancer and human immunodeficiency virus infection, DNA vaccine have being designed or tested in clinical trails [8] [9] [10] . We previously constructed a DNA vaccine encoding glycoprotein D (gD) of HSV-1 and interleukin (IL)-21 [11] . There, gD serves as major immunogen and IL-21 is an adjuvant molecular for the purpose of improving the entire immune outcome. After being tested, this DNA vaccine showed protective against primary HSK, but had limited effect when dealing with recurrent HSK. Therefore, more efficient HSV-1 DNA vaccine should be developed. Different from primary HSK, recurrent HSK occurs in the condition of preexistence of certain HSV-1 neutralizing antibody. One of the most important reasons explaining why neutralizing antibody can't eliminate virus is evolved immune evasion mechanism of HSV-1. A total of 12 glycoproteins were reported on the surface of HSV-1 [12] . Among them, gD and glycoprotein B (gB) can elicit strong specific immune response against HSV-1, while glycoprotein C (gC) plays a critical role in mediating immune evasion of HSV-1 [13] [14] . As we all known, complement serving as a major none-specific immune response in body is vital for controlling virus infection [15] . However, gC can disrupt the process of complement activation via binding complement C3b and blocking the C5 and properdin interaction with C3b, thereby benefiting virus infection [16] [17] [18] .
Strategies to prevent gC mediated immune evasion may be required to develop successful HSV vaccines. Chang et al [19] reported that immunization with gC of HSV-1 could totally blocks C3b binding and reduces disease severity. However, gC is not very immunogenic and gC alone can't induce sufficient immune protective effect against HSV-1 disease [20] . Recent studies focus on investigating whether combination gC and gD will have a better therapeutic effect to HSV disease, compared to gC or gD alone. It has been reported that immunizing mice with gD and gC proteins provided better protection than gD alone in preventing HSV-1 or HSV-2 associated infectious diseases [21] [22] . However, DNA vaccine encoding gC and gD for HSK treatment have not been reported. In this study, we developed a DNA vaccine construct pRSCgC.gD-IL21 by fusing gC sequence of HSV-1 with gD and using IL-21 which is well-known adjuvant molecular. Considered the fact that the efficiency of DNA membrane associated transport is extreme low and DNA can be degraded easily without protection, therefore a suitable carrier is needed [23] [24] . Chitosan, as a natural cationic polysaccharide, can easily combine with the negatively charged plasmid DNA and has the properties of being easily absorbed and biodegraded, allowing gene slow release and long lasting expression, low toxicity and cost, enhancing the immune response, have been widely used as DNA carrier [25] [26] . Here, we embedded the plasmid DNA into chitosan to form DNA plasmid/chitosan nanoparticle for immunization. Besides DNA carrier, the inoculation approach also matters. We previously demonstrated that topically administration of nanoparticle-loaded DNA vaccine could induce stronger ocular local immune response of mice than intramuscular inoculation [27] . What's more, it has been noted that nanoparticle could benefit local inoculation by inducing strong local mucosal immunity [28] [29] . Therefore, we adopted topical immunization in this study. Here, we reported that we successfully constructed gC-based vaccine termed pRSC-gC.gD-IL21 and investigated its effect against primary HSK. This study provided the experimental fundaments for further investigating this vaccine in dealing with recurrent HSK which is the key point for HSK management.
MATERIALS AND METHODS
Mice, Cell Lines and Virus Balb/c background female mice (4-6wk) were purchased from the Animal Center of Yangzhou University for experimental use. And mice were maintained under pathogen free conditions with a 12h/12h light-dark cycle. Vero cells derived from African green monkey kidney were preserved in our lab. SP2/0 cells derived from Balb/c mice myeloma cells and YAC-1 cells derived from moloney leukemia-induced T cell lymphoma, were acquired from Cellular Institute of China in Shanghai. All the cells were cultured in RPMI1640 containing 10% fetal bovine serum, 100 units/mL penicillin G sodium and 100 g/mL streptomycin sulfate at 37℃ in 5% CO 2 atmosphere. HSV-1 strain F was obtained from the Institute of Virology in Wuhan, China. All the animal experiments were strictly in accordance with the guidelines of the Animal Research Ethics Board of Southeast University, China. Plasmids and Primers Recombined pRSC-gD-IL21 plasmid were constructed and preserved in our lab. The gC gene (whole extracellular sequence from Gly25 to Gly480) was harvested by polymerase chain reaction (PCR) amplifying with a pair of specific primers to the gC gene (forward: 5'-TTTA-CAAGCTTGGCTCGGAAACTGCCTCCAC-3', reverse: 5'-ATATGGCTAGCTCATTGCCCCCACCCACTCGATCG-CCTCGA-3') and HSV-1 gene was used as template. The gD (whole extracellular sequence from Met1 to Met340)-linker gene was obtained by double time PCR. Briefly, pRSC-gD-IL21 was set as template for the first round amplifying with a pair of specific primers (forward: 5'-ATATGGGTACCG-CCGCCACCATGGGGGGGGCTGCCGCCA-3', reverse: 5'-CCACCCGAACCTCCACCTTHCCATGTTGTTCGGG-GTGGCCGGGGGAT-3'). The product of first round PCR was used as template for the second round PCR and the primers are 5'-ATATGGGTACCGCCGCCACCATGGGGGGGGCTG-CCGCCA-3'(forward), and 5'-GCCAAGCTTAGAACCTC-CACCTGAACCTCCACCCGAACCTCCACCCATG-3'(reverse). Construction and Identification of pRSC-gC.gD-IL21 DNA Vaccine We firstly prepared the plasmid pRSC-gD-Linker-IL21.pRSC-IL21, which was obtained by removing the gD sequence from pRSC-gD-IL21, was connected with gD linker DNA and finally formed pRSC-gD-Linker-IL21. After being digested by HindIII and NheI, gC DNA was connected with pRSC-gD-Linker-IL21 and finally developed the plasmid pRSC-gC.gD-IL21 DNA, which was identified by the analysis . After incubation for 4h, the transfected cells were washed with RPMI1640 to remove the free nanoparticle mixtures, and the cells were further cultured for 48h. For Western blot, the cell were harvested and homogenized in RIPA buffer containing Tris-HCl (50 mmol/L), NaCl (150 mmol/L), EDTA (1 mmol/L), Triton-X (1%), sodium deoxycholate (0.5%) and SDS (0.1%). Then, the homogenates were centrifuged at 13 000 r/min for 15min at 4℃ and the supernatant was acquired as extracted protein.
After electrophoresis, proteins were transferred on PVDF membranes. The membranes were soaked in 5% milk/PBST for 2h at room temperature. And then, the membranes were incubated with anti-gD antibody for 1h. The following steps were performed according to the Western-Breeze Kits protocol (Invitrogen, USA).
Preparation and Examination of Chitosan/DNA Nanoparticle
Chitosan was dissolved in NaAc (5 μmol/L, pH5.5) solution at a ratio of 0.02% (w/v). Plasmid DNA (0.8 μg) was diluted in Na 2 SO 4 (5 mmol/L) solution. After bathing in water (55℃) for 10min, chitosan solution and DNA solution were mixed by vortex at equal volume, and the mixture was stored for experimental use. For the purpose of examining the loading efficiency, the naked plasmid DNA, precipitation of chitosan/ DNA nanoparticle and supernant of chitosan/DNA nanoparticle were subjected to agarose gel electrophoresis. DNA bands were visualized by EtBr. To determine the protective effect of chitosan on plasmid DNA, the naked plasmid DNA and chitosan/DNA nanoparticle were digested by DnpI and the products were subjected to agarose gel electrophoresis, DNA bands were visualized by EtBr. Vaccine Immunization and Virus Challenge in Mice Mice (n=12) were randomly divided into 4 groups: pRSC-gC.gD-IL21/chitosan group; pRSC-gD-IL21/chitosan group; pRSC/ chitosan group and chitosan group. The plasmid DNA/chitosan (20 μL containing 100 µg DNA) or chitosan were dropped into conjunctival sacs of each mice. The total immunization was 3 times and with 2wk interval. Two weeks after the last immunization, the mice (n=6) were sacrificed for determining immune efficiency. And, the rest received HSV-1 challenge experiments as previous described. Briefly, after being anesthetized by ketamine (100 mg/kg, i.p.), the corneas of mice were scarified 10 times with a needle and were inoculated with HSV-1 [10 μL of 7.1×10 6 plaque forming unit (PFU)/mL]. The pathological changes of epithelial or stromal were examined by ophthalmological slit lamp microscope for 15 consecutive days after HSV-1 challenge. Epithelial or stromal lesions were scored as previous described [30] .
Measurement of Anti-HSV Neutralizing Antibody in
Serum Two weeks after final immunization, blood were drew from mice by retro-orbital bleeding and centrifuged at 3500 r/min for 15min, then serum were gathered and inactivated in water bath (55℃) for 30min. A two-fold series of dilutions of sera was incubated with an equal volume of the virus (7.1×10 6 TCID 50/mL). And, the mixture was added in the cultured vero cells for 72h. Cell pathological changes were observed by microscope. The antivirus neutralizing antibody titer was calculated as the reciprocal of the dilution which resulted in 50% reduction in virus titer. Measurement of sIgA in Mice Tears For tear collection, a small swab was inserted carefully inside the lower lid of the eyes of an immunized mouse for 5min and this was repeated 5 times at 1h intervals. The swabs were soaked in 0.1 mL phosphate buffer saline (PBS) over night at 4℃. A two-fold dilution of extracted tear was prepared for detecting sIgA by enzyme-linked immunosorbent assay (ELISA). Briefly, tear samples were added in 96-well plates which were coated with anti HSV-1 gD (10 μg/mL) antigen and the plate were kept overnight at 4℃. After being washed in PBS for 3 times, the goat anti mice IgA-HRP antibody were added in the wells for 1h at room temperature. After visualization by DAB, the plates were read at an optical density of 490 nm by using a Fusion or Victor 31420 plate reader (Perkin Elmer, USA).
Measurement of Cellular Immune Responses
Two week after last immunization, the mice were sacrificed and spleen was removed. And then, single cell suspension of spleen at a density of 1×10 6 /mL was prepared as effector cells. The SP2/0 cells which have been transfected with pRSC-gD-IL21/chitosan nanoparticle and YAC-1 cells (not transfected) were set as target cells of splenocytes and nature killer cells (NK) respectively. The target cells were adjusted to a density of 1×10 4 /mL and cultured in RPMI1640 containing 10%
fetal bovine serum at 37℃ in 5% CO 2 atmosphere for 48h. The effector cells were co-cultured with target cells at a ratio of 50:1 and cytotoxicity was detected by LDH release. The detailed procedures of LDH release test were described in manufacturer's instructions (Genmed Scientifics).
Data Analysis
All the values were represented as mean±SD. Unpaired Sudent's t-test was used for comparison between 2 groups, whereas Kruskal-Wallis H test was used for the statistic of clinical data. Data analysis was performed with SPSS9.0.
RESULTS

Identification of Constructed pRSC-gC.gD-IL21 DNA
Vaccine To validate whether the pRSC-gC.gD-IL21 DNA vaccine was constructed successfully, the plasmid were sequenced. The gC sequences we detected are 99.12% consistent with the data existed in the Genebank (only 4 amino acids are different, including P132S, F299L, H306R, I383H), and the gD sequences are 98.22% with only 7 different amino acids, including L50P, Q52R, N71D, T217A, P295Q, V361G, P374R. We consider that these rare mutated sits are due to the different strains of HSV-1 and couldn't affect its function. For further confirmation, the pRSC-gC.gD-IL21 were digested by HindIII/NheI or Hind/NheI and the products were subjected to agarose gel electrophoresis. We observed a 2454 bp DNA band which is equal to the length of gD+gC and a 1393 bp gC DNA band in the gel ( Figure 1A) . To test the packaging efficiency of chitosan to plasmid DNA, the mixture of pRSC-gC.gD-IL21 DNA/nanoparticle was centrifuged and DNA content in the supernant and precipitation were detected by ultraviolet spectrophotometer. The ratio of pRSC-gC.gD-IL21 DNA in chitosan nanoparticle was near 97% and this was further confirmed by agarose gel electrophoresis. Result showed that there was almost no visualized DNA band for supernant ( Figure 1B) . Furthermore, the electrophoresis analysis revealed that chitosan nanoparticle could efficiently protect the pRSC-gC.gD-IL21 DNA against DnpI ( Figure 1C ). Western blot analysis revealed that a 117 Kd protein (gD+gC) existed in pRSC-gC.gD-IL21 DNA/chitosan nanoparticle transfected 293T cells ( Figure 1D ). These results demonstrated that the pRSC-gC.gD-IL21 DNA vaccine was constructed successfully.
The Levels of HSV-1 Neutralizing Antibody and sIgA in Immunized Mice
To examine the humoral immune responses in immunized mice, we detected the levels of HSV-1 neutralizing antibody and sIgA. Results showed that the levels of HSV-1 neutralizing antibody in pRSC-gC.gD-IL21 DNA/ chitosan immunized mice were near ten folds of the mice immunized with pRSC-gD-IL21 DNA/chitosan and the pRSC/ chitosan or chitosan immunized mice showed the lowest levels of HSV-1 neutralizing antibody. In addition, the levels of sIgA in tear of pRSC-gC.gD-IL21 DNA/chitosan immunized mice is highest, with intermediate levels of sIgA in tear of pRSCgD-IL21 DNA/chitosan immunized mice and relatively lower levels in tear of pRSC/chitosan or chitosan immunized mice ( Figure 2 ). These results demonstrated that pRSC-gC.gD-IL21 DNA/chitosan vaccine could effectively induced humoral immune responses in mice. Cellular Immune Response to DNA Vaccine To determine cellular immune response in immunized mice, we investigated the cytotoxic activities of NK cells or splenocytes. Results showed that pRSC-gC.gD-IL21 DNA/chitosan immunized mice exhibited the highest NK and splenocytes activities, followed by pRSC-gD-IL21 DNA/chitosan immunized mice, and the lowest were pRSC/chitosan and chitosan immunized mice ( Figure 3 ). These results indicated that pRSC-gC.gD-IL21 DNA/chitosan conferred the most robust cellular immune response to gD on mice compared with that of pRSC-gD-IL21 DNA/chitosan or mocked plasmid vaccine.
Clinical Keratitis of Vaccine Immunized Mice After Virus
Challenge The vaccine immunized mice were inoculated with HSV-1 virus and the pathological changes of corneas were monitored daily for 15d. After virus challenge, pRSC-gC.gD-IL21 DNA/chitosan immunized mice showed the least severe herpes keratitis and got a total recovery by day 5, while the mocked plasmid/chitosan or chitosan exhibited the most severe 
DISCUSSION
It has been reported that gC play a critical role in mediating the immune evasion of HSV-1 and the strategy targeting to gC represents a promising approach to control the spread of virus [19, [31] [32] . Several studies demonstrated that gC could effectively enhance gD induced immune protection against HSV disease [21] [22] . In present study, we developed a gC based DNA vaccine called pRSC-gC.gD-IL21 DNA vaccine by fusing gD sequence of HSV-1 to gC of HSV-1, and we demonstrated that pRSC-gC.gD-IL21 DNA vaccine could induced strongest humoral and cellular immune response to protect mice against primary HSK, when compared with pRSC-gD-IL21 DNA vaccine. First of this study, we examined whether our gC based DNA vaccine was developed successfully. Endonuclease digestion experiments revealed that our vaccine constructed successfully. Given low efficiency of cell entry for naked DNA, we loaded DNA vaccine in chitosan to form the DNA/chitosan nanoparticle. After being tested, the chitosan nanoparticle could effectively carry the DNA vaccine, with 97 percent of loading efficiency and protect the DNA vaccine from DnpI. Furthermore pRSC-gC.gD-IL21 DNA/chitosan nanoparticle transfected cells could effectively produced fusion protein gD plus gC. These results demonstrated that gC based DNA vaccine was developed successfully. It is known that a successful vaccine should be able to induce both high level of humoral and cellular immune response.
In this study, we found that chitosan nanoparticle containing pRSC-gC.gD-IL21 DNA immunized mice produced more HSV-1 neutralizing antibody in serum and sIgA in tear when compared with that of pRSC-gD-IL21 DNA vaccine or mock DNA vaccine immunized mice. What's more, cellular immune responses reflected by splenocytes and NK activities in pRSC-gC.gD-IL21 DNA/chitosan immunized mice were the strongest among 4 groups. Above results were consistent with the observations that the corneal pathological grade of pRSCgC.gD-IL21 DNA/chitosan immunized primary HSK mice was the lowest, and got a total recovery by day 5 while pRSC-gD-IL21 DNA/chitosan immunized primary HSK mice got a total recovery by day 10. These results are similar with the study by Awasthi et al [22] demonstrating that immunization with a vaccine combining herpes simplex virus 2 (HSV-2) gC and gD proteis improved the protection of dorsal root ganglia in mice compared to immunization with gD alone. In their study, they also observed that gD and gC protein combination immunized animals showed a higher level neutralizing antibody, enhanced cellular immune response and less disease. However, it is the first time for our study to report DNA vaccine expressing fusion protein gD and gC for HSK treatment.
In conclusion, this study demonstrated that chitosan nanoparticles loading pRSC-gC.gD-IL21 DNA vaccine could effectively alleviate symptoms of herpes keratitis caused by HSV-1 primary infection in mice via inducing robust humoral and cellular immune response. This study laid the foundation of investigating this DNA vaccine in recurrent HSK treatment.
